|
US6641809B1
(en)
|
1990-03-26 |
2003-11-04 |
Bristol-Myers Squibb Company |
Method of regulating cellular processes mediated by B7 and CD28
|
|
US7070776B1
(en)
|
1990-03-26 |
2006-07-04 |
Bristol-Myers Squibb Company |
Methods for blocking binding of CD28 receptor to B7
|
|
US6071716A
(en)
|
1990-10-01 |
2000-06-06 |
Dana-Farber Cancer Institute |
DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
|
|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
US6824779B1
(en)
|
1993-07-26 |
2004-11-30 |
Dana-Farber Cancer Institute, Inc. |
Methods for inhibiting the interaction of B7-2 with its natural ligand
|
|
US5858776A
(en)
|
1993-11-03 |
1999-01-12 |
Repligen Corporation |
Tumor cells with increased immunogenicity and uses therefor
|
|
US6130316A
(en)
|
1993-07-26 |
2000-10-10 |
Dana Farber Cancer Institute |
Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
|
|
US6218510B1
(en)
|
1994-03-02 |
2001-04-17 |
Brigham & Woman's Hospital |
B7-1 and B7-2 polypeptides
|
|
ES2153895T3
(es)
|
1994-03-08 |
2001-03-16 |
Dana Farber Cancer Inst Inc |
Metodos para modular la insensibilidad de celulas t.
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
CA2257861A1
(en)
|
1996-06-14 |
1997-12-18 |
Smithkline Beecham Corporation |
Hexameric fusion proteins and uses therefor
|
|
US6491925B2
(en)
|
1996-08-15 |
2002-12-10 |
Emory University |
Compositions and methods for cancer prophylaxis and/or treatment
|
|
CA2292415A1
(en)
|
1997-06-20 |
1998-12-30 |
Innogenetics N.V. |
B7-binding molecules for treating immune diseases
|
|
US7011833B1
(en)
|
1999-05-06 |
2006-03-14 |
Genetics Institute, Inc. |
Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
|
|
US6429303B1
(en)
|
1999-09-03 |
2002-08-06 |
Curagen Corporation |
Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
|
|
US7064111B1
(en)
|
1999-10-05 |
2006-06-20 |
Georgetown University |
Use of soluble costimulatory factor for tumor immuno-gene therapy
|
|
US6756481B2
(en)
|
2000-05-10 |
2004-06-29 |
Schering Corporation |
IL-23 receptor binding compositions
|
|
US7183376B2
(en)
|
2000-06-23 |
2007-02-27 |
Maxygen, Inc. |
Variant B7 co-stimulatory molecules
|
|
US20040236091A1
(en)
|
2001-03-28 |
2004-11-25 |
Chicz Roman M. |
Translational profiling
|
|
AU2002368044A1
(en)
|
2001-06-22 |
2004-04-19 |
Maxygen, Inc. |
Co-stimulatory molecules
|
|
AU2002346373A1
(en)
|
2001-11-09 |
2003-05-19 |
Idec Pharmaceuticals Corporation |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
|
DK1638941T3
(da)
|
2003-05-22 |
2010-10-11 |
Abbott Lab |
Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer
|
|
SG144925A1
(en)
|
2003-08-04 |
2008-08-28 |
Bristol Myers Squibb Co |
Methods for treating cardiovascular disease using a soluble ctla4 molecule
|
|
CA2585776A1
(en)
|
2004-10-29 |
2006-05-11 |
University Of Southern California |
Combination cancer immunotherapy with co-stimulatory molecules
|
|
EP2083081A1
(en)
|
2005-07-22 |
2009-07-29 |
Five Prime Therapeutics, Inc. |
Compositions and methods of treating disease with FGFR fusion proteins
|
|
WO2007123737A2
(en)
|
2006-03-30 |
2007-11-01 |
University Of California |
Methods and compositions for localized secretion of anti-ctla-4 antibodies
|
|
WO2008037080A1
(en)
|
2006-09-29 |
2008-04-03 |
Universite De Montreal |
Methods and compositions for immune response modulation and uses thereof
|
|
WO2008119071A1
(en)
|
2007-03-28 |
2008-10-02 |
Biogen Idec Inc. |
Modulation of tumor microenvironment
|
|
US20100189716A1
(en)
|
2007-03-28 |
2010-07-29 |
Biogen Idec Inc. |
Treatment of hodgkins lymphoma
|
|
SI2856876T1
(en)
|
2007-03-30 |
2018-04-30 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
US20100285039A1
(en)
|
2008-01-03 |
2010-11-11 |
The Johns Hopkins University |
B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells
|
|
KR20160070165A
(ko)
|
2008-02-08 |
2016-06-17 |
메디뮨 엘엘씨 |
Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
|
|
JP2012500855A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
|
|
AU2009288730B2
(en)
|
2008-08-25 |
2013-06-20 |
Amplimmune, Inc. |
Compositions of PD-1 antagonists and methods of use
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
CN103796681B
(zh)
|
2011-06-30 |
2018-07-20 |
建新公司 |
T细胞活化的抑制剂
|
|
MX368257B
(es)
|
2011-08-01 |
2019-09-26 |
Genentech Inc |
Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
|
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
US9567642B2
(en)
|
2012-02-02 |
2017-02-14 |
Massachusetts Institute Of Technology |
Methods and products related to targeted cancer therapy
|
|
WO2013116656A1
(en)
|
2012-02-03 |
2013-08-08 |
Emory University |
Immunostimulatory compositions, particles, and uses related thereto
|
|
US20140377253A1
(en)
|
2013-03-15 |
2014-12-25 |
Abbvie Biotherapeutics Inc. |
Fc variants
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
WO2014144621A2
(en)
|
2013-03-15 |
2014-09-18 |
Pyranose Biotherapeutics, Inc. |
Modified fc fusion proteins
|
|
BR112015023120A2
(pt)
|
2013-03-15 |
2017-11-21 |
Genentech Inc |
método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
|
|
ES2714708T3
(es)
|
2013-10-01 |
2019-05-29 |
Mayo Found Medical Education & Res |
Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
|
|
EP3087099A4
(en)
|
2013-12-23 |
2017-07-19 |
Oncomed Pharmaceuticals, Inc. |
Immunotherapy with binding agents
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
RU2715038C2
(ru)
*
|
2014-07-11 |
2020-02-21 |
Дженентек, Инк. |
Антитела анти-pd-l1 и способы их диагностического применения
|
|
EP3194440A1
(en)
|
2014-09-15 |
2017-07-26 |
F. Hoffmann-La Roche AG |
Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists
|
|
US10584157B2
(en)
|
2015-03-16 |
2020-03-10 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd |
Isolated peptides derived from the B7 ligand dimer interface and uses thereof
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
CN121159719A
(zh)
|
2015-04-17 |
2025-12-19 |
高山免疫科学股份有限公司 |
具有可调的亲和力的免疫调节蛋白
|
|
HRP20200439T1
(hr)
|
2015-04-30 |
2020-06-12 |
Psioxus Therapeutics Limited |
Onkolitički adenovirus koji kodira protein b7
|
|
HUE068868T2
(hu)
|
2015-07-30 |
2025-02-28 |
Macrogenics Inc |
PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
|
|
CN106397592A
(zh)
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
|
|
WO2017042814A1
(en)
|
2015-09-10 |
2017-03-16 |
Yeda Research And Development Co. Ltd. |
Use of perforin positive immature dendritic cells in disease treatment
|
|
CN108513576A
(zh)
|
2015-09-14 |
2018-09-07 |
高山免疫科学股份有限公司 |
可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗
|
|
US10273281B2
(en)
|
2015-11-02 |
2019-04-30 |
Five Prime Therapeutics, Inc. |
CD80 extracellular domain polypeptides and their use in cancer treatment
|
|
BR112018012180A2
(pt)
|
2015-12-17 |
2018-12-04 |
Psioxus Therapeutics Ltd |
vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
|
|
US20190048085A1
(en)
|
2016-02-25 |
2019-02-14 |
Cell Medica Switzerland Ag |
Modified cells for immunotherapy
|
|
WO2017151818A2
(en)
|
2016-03-02 |
2017-09-08 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
HRP20240052T1
(hr)
|
2016-03-04 |
2024-03-29 |
Io Biotech Aps |
Kombinirana terapija protiv raka
|
|
WO2017181152A2
(en)
|
2016-04-15 |
2017-10-19 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
MX2018012472A
(es)
|
2016-04-15 |
2019-08-12 |
Alpine Immune Sciences Inc |
Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
|
|
JP2019519516A
(ja)
|
2016-05-18 |
2019-07-11 |
モデルナティーエックス， インコーポレイテッド |
がんの治療のためのｍＲＮＡ併用療法
|
|
WO2017201210A1
(en)
|
2016-05-18 |
2017-11-23 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
BR112019005964A2
(pt)
|
2016-09-27 |
2019-06-18 |
Epicentrx, Inc. |
proteínas de fusão imunomoduladoras
|
|
WO2018075978A1
(en)
|
2016-10-20 |
2018-04-26 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
KR20190139216A
(ko)
|
2017-04-28 |
2019-12-17 |
파이브 프라임 테라퓨틱스, 인크. |
Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
|
|
CN112543642A
(zh)
|
2018-08-29 |
2021-03-23 |
戊瑞治疗有限公司 |
CD80胞外结构域Fc融合蛋白给药方案
|
|
US12589132B2
(en)
|
2019-02-22 |
2026-03-31 |
Five Prime Therapeutics, Inc. |
CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
|
|
EP3963079A1
(en)
|
2019-05-03 |
2022-03-09 |
Five Prime Therapeutics, Inc. |
Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins
|